Cross Current Guidelines from the ADA and EASD have also indicated that personalized strategies for people with T2DM should include using GLP-1 receptor agonists as cornerstone therapy in efforts to reduce glycemia driven risk, as well as cardiovascular risks [127]. Here, GLP1R is linked to type 2 diabetes mellitus.